Drugs / Peluntamig
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05652686 | Sep 2023 → Dec 2027 expected | digestive system neuroendocrine neoplasm, large cell neuroendocrine carcinoma, prostate neuroendocrine neoplasm, small cell lung carcinoma | Phanes Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Peluntamig | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05652686 ↗ |
| Known as | PT217 | “Peluntamig (PT217)” NCT05652686 ↗ |
| Target | CD47 | “A bispecific antibody (bsAb) against DLL3 and CD47.” NCT05652686 ↗ |
| Target | DLL3 | “A bispecific antibody (bsAb) against DLL3 and CD47.” NCT05652686 ↗ |